Loading
A phase 1 trial of OPB-101 run by Outpace Bio, Inc., terminated.
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer is a phase 1 interventional study registered as NCT07030907 by Outpace Bio, Inc., with 3 participants enrolled, started 2025-06-16. Conditions recorded: Ovarian Cancer Recurrent, Ovarian Cancer and Platinum Resistant Ovarian Cancer. Interventions recorded: OPB-101.
Shares Outpace Bio, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Outpace Bio, Platinum-resistant ovarian cancer and the tag pipeline.
Shares Outpace Bio and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/